# Lanshan Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lanshan-biotechnology

- Industry: Biotechnology
- Headquarters: Beijing, China
- Latest round: Angel (Jul 15, 2026)
- Investors on record: 5

## About

Based in Beijing, China and founded in 2023, Lanshan (Beijing) Biotechnology Co., Ltd., trading as Lanshan Biotechnology, operates as a biomedical service provider, mainly engaged in the research and development of innovative drugs for neuropsychiatric diseases. The chief scientist, Dr. Yao Jun, is an Associate Professor at the School of Life Sciences, Tsinghua University. In 2023, the company closed a seed funding from new investors Innoangel Fund and Tusstar. In July 2026, Lanshan Biotechnology raised an angel+ funding from Syn Capital, Baiying Bio-industry Investment, Renxi Fund and other investors.

Lanshan Biotechnology is mainly engaged in the research and development of innovative drugs for neuropsychiatric diseases, and has a pipeline of drugs for multiple indications such as bipolar disorder and depression. The company independently developed an iPSC organoid drug development platform.

The company generates revenue by developing innovative drugs for neuropsychiatric diseases such as bipolar disorder and depression.

## Funding rounds

- Angel, Jul 15, 2026 — Baiying Bio-industry Investment, Syn Capital, Renxi Fund
- Seed, Jun 1, 2023 — TusStar, Innoangel Fund

## Investors

- TusStar (https://capitalatlas.ai/funds/tusstar) — Seed
- Innoangel Fund (https://capitalatlas.ai/funds/innoangel-fund) — Seed
- Baiying Bio-industry Investment (https://capitalatlas.ai/funds/baiying-bio-industry-investment) — Angel
- Syn Capital — Angel
- Renxi Fund — Angel